Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.70 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.70 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | HPN | P05981 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20522295 | 0.92 | CSNK2A2 (0.60) | CSNK2A2CSNK2A1CSNK2BHDAC1HDAC2 | |
| SCHEMBL4459490 | 0.85 | HDAC1 (0.62) | CSNK2A2CSNK2A1HDAC1HDAC2BLM | |
| SCHEMBL9893004 | 0.83 | CSNK2A2 (0.74) | CSNK2A2CSNK2A1CSNK2BMAPTKDM4E | |
| SCHEMBL7930408 | 0.80 | HDAC1 (0.67) | CSNK2A2CSNK2A1CSNK2BHDAC1HDAC2 | |
| SCHEMBL22712383 | 0.79 | SMN1; SMN2 (0.48) | CSNK2A2CSNK2A1CSNK2BHDAC1HDAC2 | |
| SCHEMBL11386451 | 0.79 | ALDH1A1 (0.58) | CSNK2A2CSNK2A1HDAC1HDAC2BLM | |
| SCHEMBL28352308 | 0.78 | SMN1; SMN2 (0.47) | CSNK2A2CSNK2A1CSNK2BHDAC1HDAC2 | |
| SCHEMBL22532425 | 0.78 | CSNK2A2 (0.62) | CSNK2A2CSNK2A1HDAC1HDAC2MAPT | |
| SCHEMBL21725106 | 0.77 | SMN1; SMN2 (0.56) | CSNK2A2CSNK2A1CSNK2BBLMHPN | |
| SCHEMBL28348731 | 0.77 | RAB9A (0.52) | CSNK2A2CSNK2A1HDAC1HDAC2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | CSNK2A2 1475/4885CSNK2A1 1576/4885CSNK2B 1321/4885 |
| US-20200377493-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | CSNK2A2 2574/4885CSNK2A1 2963/4885CSNK2B 2363/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | CSNK2A2 2981/4885CSNK2A1 3311/4885CSNK2B 2760/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | CSNK2A2 1717/4885CSNK2A1 2297/4885CSNK2B 1440/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | CSNK2A2 2943/4885CSNK2A1 3018/4885CSNK2B 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.